Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nilotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 16/20 | 0.99 |
| ▸ | BCR known ✓ | P11274 | 8/20 | 0.99 |
| ▸ | KIT | P10721 | 11/20 | 0.99 |
| ▸ | LDLR | P01130 | 8/20 | 0.99 |
| ▸ | PCSK9 | Q8NBP7 | 8/20 | 0.99 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.99 |
| ▸ | LCK | P06239 | 4/20 | 0.99 |
| ▸ | LYN | P07948 | 4/20 | 0.99 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.99 |
| ▸ | FLT3 | P36888 | 4/20 | 0.99 |
| ▸ | DDR2 | Q16832 | 4/20 | 0.99 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.99 |
| ▸ | SRC | P12931 | 2/20 | 0.99 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.99 |
| ▸ | CA12 | O43570 | 1/20 | 0.99 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.99 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.99 |
| ▸ | STK10 | O94804 | 1/20 | 0.99 |
| ▸ | CA1 | P00915 | 1/20 | 0.99 |
| ▸ | CA2 | P00918 | 1/20 | 0.99 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nilotinib SCHEMBL29580067 | 0.99 | ABL1 (1.00) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL7901 | 0.99 | ABL1 (1.00) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL29366964 | 0.99 | ABL1 (1.00) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28569394 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL434496 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1984397 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL28656586 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL31005052 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL1459790 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 | |
| Nilotinib SCHEMBL26181009 | 0.99 | ABL1 (0.99) | ABL1KITBCRLDLRPCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635015-A | Pharmaceutical composition | 深圳市药欣生物科技有限公司 | 2023-08-22 | — | — | CN | claimed |
| EP-4221690-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-08-09 | — | — | EP | claimed |
| EP-2966072-A2 | CRYSTALLINE FORMS OF NILOTINIB HYDROBROMIDE, SUCCINATE, GLUTAMATE, ACETATE, L-MALATE AND MALEATE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-01-13 | — | — | EP | claimed |
| US-8937082-B2 | Nilotinib salts and crystalline forms thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-01-20 | — | — | US | claimed |
| US-20130158059-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-06-20 | — | — | US | claimed |
| EP-2571863-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2013-03-27 | — | — | EP | claimed |
| WO-2011163222-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-29 | — | — | WO | claimed |
| US-20230414613-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-12-28 | — | — | US | disclosed |
| CN-116635015-A | Pharmaceutical composition | 深圳市药欣生物科技有限公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-4221690-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2023-08-09 | — | — | EP | disclosed |
| CN-112294971-B | Nilotinib compositions having improved solubility | 深圳市泰力生物医药有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-112294971-A | Nilotinib compositions having improved solubility | 深圳市泰力生物医药有限公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-2909191-B1 | MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING NILOTINIB AND SELECTED CO-CRYSTAL FORMERS | BASF SE (DE) | 2019-03-20 | — | — | EP | disclosed |
| WO-2015092624-A1 | NILOTINIB MONO-OXALATE AND ITS CRYSTALLINE FORM | RANBAXY LABORATORIES LIMITED (IN) | 2015-06-25 | — | — | WO | disclosed |
| US-20150099885-A1 | Nilotinib Salts And Crystalline Forms Thereof | TEVA PHARMA (IL) | 2015-04-09 | — | — | US | disclosed |
| US-8937082-B2 | Nilotinib salts and crystalline forms thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2015-01-20 | — | — | US | disclosed |
| WO-2014060449-A1 | MULTICOMPONENT CRYSTALLINE SYSTEM COMPRISING NILOTINIB AND SELECTED CO-CRYSTAL FORMERS | BASF SE (DE) | 2014-04-24 | — | — | WO | disclosed |
| US-20130158059-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-06-20 | — | — | US | disclosed |
| EP-2571863-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011163222-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414613-A1 | PHARMACEUTICAL COMPOSITIONS | ABL1, ABCG2, LIPA | ABL1 1/4885BCR 89/4885KIT 247/4885 |
| US-20150099885-A1 | Nilotinib Salts And Crystalline Forms Thereof | ABL1, TP53, NRAS | ABL1 1/4885BCR 24/4885KIT 1401/4885 |
| US-20130158059-A1 | NILOTINIB SALTS AND CRYSTALLINE FORMS THEREOF | ABL1, TP53, NRAS | ABL1 1/4885BCR 24/4885KIT 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.